STroke Secondary Prevention With Catheter ABLation and EDoxaban for Patients With Non-valvular Atrial Fibrillation: STABLED Study

Inclusion Criteria: * Age ≥20 or ≤85 years at time of giving informed consent * Nonvalvular atrial fibrillation * History of stroke in previous 6 months * Current or planned treatment with edoxaban * Modified Rankin scale ≤3 Exclusion Criteria: * Symptomatic paroxysmal AF resistant to anti-arrhythmic drugs * Presence of left atrial thrombus and left atrial appendage on transthoracic echocardiography, computed tomography or magnetic resonance imaging * Unable to take anticoagulation therapy for any reason, including tendency to bleed or considered at high risk for bleeding from anticoagulation therapy. * Presence of severe renal disorder (estimated creatinine clearance \<30 mL/min by Cockroft-Gault equation) * Previous CA or surgical intervention for AF * History of treatment with a left atrial appendage closure device * Left atrial diameter ≥55 mm on transthoracic echocardiography * Ejection fraction ≤35% on transthoracic echocardiography * Persistent AF for ≥10 years * Pregnant or possibility of pregnancy * Unlikely to complete the study, such as due to progressive malignant tumor * Participating or planning to participate in another clinical trial * Unwilling to participates * Judged as incompatible for the study by the investigators